[ET Net News Agency, 11 December 2025] UBS lowered the target price for Giant Biogene
(02367) to HKD39.5 from HKD79.5 and downgraded the rating to "neutral" from "buy".
The research house said it is turning more cautious about the near-term sales growth
outlook and expects Giant Biogene's sales growth to decelerate to 5% during 2026-28. (rc)